This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
Voluntarily join this study and sign the informed consent form;
Age ≥ 18 years;
Expected survival time ≥ 3 months;
Unresectable metastatic castration-resistant prostate cancer;
Patients with metastatic castration-resistant prostate cancer who are suitable for radical local therapy;
Patients with non-prostatic acinar adenocarcinoma confirmed by histopathology or cytology, among others;
Patients who have previously received antibody-drug conjugates using topoisomerase I inhibitors as the toxin, among others;
Use of chemotherapy, targeted therapy, biological therapy, etc., within 4 weeks or 5 half-lives prior to study randomization;
Sichuan Baili Pharmaceutical Co., Ltd.
Lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Collaborator